Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathwaysYmera Pignochino, Massimo Aglietta|Molecular Cancer|2009Cited by 176
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomasYmera Pignochino, Francesco Leone|BMC Cancer|2010Cited by 174
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical modelsYmera Pignochino, Giovanni Grignani|Molecular Cancer|2017Cited by 70
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular InsightsGiulia Chiabotto, Ymera Pignochino|Cancers|2020Cited by 31